Pain control and anxiety management for periodontal therapies
Year: 2008
Type: review
Abstract: Successful management of periodontal disease relies on a variety of relatively minor oral surgical procedures including dental prophylaxis, scaling and root planing, gingivectomies, gingival grafts, and various gingival flap procedures. Strategies for pain control and anxiety management in periodontics are tailored to address some of the unique features of these treatments. Local anesthesia and sedation are used extensively when providing periodontal therapies to help patients undergo painless surgical treatments with minimal physiological and psychological stress. Established techniques for sedation and anesthesia guidelines vary among countries and continents. Single- and multi-drug intravenous sedation techniques are employed using a number of different sedative drugs. A review of the pharmacology and clinical therapeutics of anesthetic and sedative agents used in the field of periodontology is presented. Alternative therapeutic strategies will also be addressed, including the use of nitrous oxide inhalation sedation and oral sedatives for enteral sedation. Two hundred years ago, surgical treatment of disease in medicine and dentistry was limited by the lack of effective means to control pain. The discovery of nitrous oxide by Joseph Priestley in 1776 fuelled the development of anesthetic and sedative techniques. Priestley realized that breathing nitrous oxide produced a very pleasurable effect and later described its analgesic properties, suggesting its potential use for surgical procedures. When a dentist in the USA, Horace Wells, successfully used nitrous oxide on himself to have a tooth extracted, this inhalation agent was further developed for use in all fields of medicine and anesthesiology. Carl Koller, at the Congress of Ophthalmologists in 1884, first officially demonstrated the local anesthetizing properties of cocaine (22). The efficacy of this first local anesthetic agent was rapidly accepted in medicine and dentistry. With the development of regional anesthetic techniques and Einhorn’s discovery in 1904 of procaine, a safer synthetic derivative of cocaine, local anesthesia became the foundation for pain control in dentistry and medicine. Intravenous sedation agents have also developed through the years with many having their original use in dental anesthesia. Many of the techniques employed ‘cocktails’ of drugs; most notably, the Jorgenson Technique, which included phenobarbitone, pethidine, and scopolamine (59). Techniques involving small incremental doses of thiopentine and methohexitone were also developed as popular methods. Often there was a fine line between general anesthesia and sedation, with the margin of safety of these techniques being very narrow. Modern sedation has evolved and developed over the last hundred years with the search for sedative agents that have a wide margin of safety and that provide conscious sedation as distinct from deep sedation/general anesthesia. The ideal drugs should be effective, acceptable to patients, easy to administer, and have a low potential for interaction with other prescribed systemic drugs. With the development of a class of drugs called the benzodiazepines, the sedation agent diazepam (Valium) was introduced in 1956. This paved the way for the provision of a safe form of sedation, permitting the relief of fear and anxiety while maintaining consciousness. With ongoing development and refinement of the benzodiazepine family of drugs, there is now sound evidence detailing their mode of action and use in the field of conscious sedation. Pharmacotherapy using a variety of central nervous system depressant agents is employed extensively to help patients undergo periodontal and restorative treatments with minimal physiological and psychological stress. The need for clear guidance on the appropriate use of a particular technique is essential to protect patient safety. Guidelines for dentists and other non-anesthetists have been developed in the USA, Australia, New Zealand, UK and other European countries (1, 2, 4, 6, 41, 51, 52, 63). The basic principles for all these guidelines are similar and vary only depending on the specific legislation for the country concerned. The Department of Health in the UK has endorsed the use of sedation as a safe alternative to general anesthesia and emphasized the importance of its development in the field of dentistry (63). The American Dental Association and the American Society of Anesthesiology also recognize that sedation is an integral part of dental practice and that it must be delivered safely and effectively (2, 4). In 2007, the American Dental Association guidelines for sedation and anesthesia were modified to address the increased use of enteral sedation and combined inhalational/enteral sedation (3). Categories of sedation and definitions of the level of consciousness were also modified to bring them into closer alignment with medical anesthesiology guidelines. Although the American Dental Association develops definitions and promotes guidelines and educational requirements, State laws control the various levels of anxiolysis, sedation, and anesthesia, and the anesthesia regulations in the USA The scope of practice established by individual State anesthesia laws has been found to vary significantly (7). Depending on the dose, route of administration, and agent(s) selected, the pharmacological strategies used to relieve fear and anxiety in ambulatory dental patients can produce the entire spectrum of central nervous system depression. Patient responses may range from minimal central nervous system depression, placing the patient at no significant risk, to complete loss of consciousness and loss of protective reflexes, as is seen when administering general anesthesia. Between these extremes, various levels of sedation have been described and categorized. By defining levels of sedation and anesthesia, regulations for training, monitoring, and medical emergency preparedness are promulgated. The boundaries between these discrete categories are often imprecise and are constantly being redefined. The American Dental Association’s 2007 revised guidelines for sedation and general anesthesia have redefined levels of anesthesia into the categories of minimal sedation, moderate sedation, deep sedation, and general anesthesia. The current categories of conscious sedation and deep sedation shown below are still used in many countries. Nevertheless, definitions of the level of sedation, central nervous system depression, and accompanying risk are essential in establishing the requirements for practice that will maximize the safety of sedation when used in dental practice. Conscious sedation has been defined as: ‘A technique in which the use of a drug or drugs produces a state of depression of the central nervous system enabling treatment to be carried out, but during which verbal contact with the patient is maintained throughout the period of sedation. The drugs and techniques used to provide conscious sedation for dental treatment should carry a margin of safety wide enough to render loss of consciousness unlikely. The level of sedation must be such that the patient remains conscious, retains protective reflexes, and is able to respond to verbal commands,’ (63). Deep sedation is defined as: ‘A drug-induced depression of consciousness during which patients cannot be easily aroused but respond purposefully following repeated or painful stimulation. The ability to independently maintain ventilatory function may be impaired. Patients may require assistance in maintaining a patent airway and spontaneous ventilation may be inadequate,’ (4). The most recent guidelines concerning the provision of conscious sedation for dental care in the UK were published in November 2003 by the Department of Health Standing Dental Advisory Committee (England and Wales) and the National Dental Advisory Committee 2006 document Conscious Sedation in Dentistry – Dental clinical guidance (Scotland) (51, 63). They have been ratified by the General Dental Council (UK) and accepted as the standard to be adhered to for those practicing sedation in the UK. The guidelines clearly state the standards that must be upheld with regard to sedation drugs and techniques, sedation and emergency equipment, staffing levels, training, and clinical governance. The established techniques for conscious sedation will vary on an international level. In the UK, for example, the recommended technique for adult dental patients is the single-drug technique using intravenous midazolam. This has a very high success rate and excellent safety profile when the standard technique is used and in patients who have been appropriately assessed. Where intravenous sedation is not indicated, inhalation and oral techniques may be considered. Outside the UK, however, other intravenous drugs, including propofol, ketamine, barbiturates, and opiates, used either individually or in combination, may be acceptable. It is important to be aware that these differences exist (6, 17, 60, 64). Anesthetic treatment modalities and specific drugs administered for third molar extraction have been recently surveyed in the USA to assess current office-based therapeutic practices. Questionnaires were mailed to a random national sample of 850 practitioners. Practicing oral and maxillofacial surgeons were estimated to perform an average of 53 third molar extraction surgery cases per month using either general anesthesia (46.3% of cases), intravenous conscious sedation (33.4% of cases), nitrous oxide sedation (5.8% of cases), oral sedation (1.7% of cases), or local anesthesia alone (12.9% of cases). For intravenous conscious sedation, a three-drug technique using midazolam, fentanyl, and propofol was most commonly reported. Ketamine and methohexital were commonly-used alternative agents for intravenous combinations (50). Because intravenous midazolam is the most universal agent employed for dental sedation, this article will concentrate on reviewing the pharmacology of midazolam. The technique of intravenous midazolam in the dental setting will be presented and its application in the field of specialist periodontal care will be discussed. Other sedation agents and techniques will be considered, including intravenous propofol, inhalation sedation with nitrous oxide and oxygen, and oral sedation techniques. Midazolam is an imidazobenzodiazepine derivative introduced into clinical practice in the UK in 1983. The unique chemical structure of midazolam confers a number of physiochemical properties that distinguish it from other benzodiazepines in terms of its pharmacological and pharmacokinetic characteristics (56). Midazolam has a fused imidazole ring that is different from other benzodiazepines such as diazepam. Midazolam’s imidazole ring helps to provide stability in solution as well as allowing for rapid metabolism. Unlike other benzodiazepines such as diazepam and lorazepam, midazolam is water-soluble because the imidazole ring is open at a pH under 4. However, when it is injected intravenously, the blood pH of 7.4 causes the imidazole ring to close and it becomes much more lipid-soluble, facilitating its rapid uptake into nerve tissue (Fig. 1). This, and the fact that it has an ionization constant (pKa) of 6.15 and is therefore poorly ionized at physiological pH, accounts for its rapid onset of action and its high protein binding in the blood (up to 97%). Metabolism includes its hydroxylation to the active metabolite 1-hydroxy-midazolam; it then undergoes glucuronidation before being renally excreted. Chemical structure of midazolam. Benzodiazepines affect γ-aminobutyric acid-mediated systems. The neurotransmitter γ-aminobutyric acid is an inhibitory neurotransmitter and controls the state of a chloride-ion channel. Activation of this chloride-ion channel results in neuronal hyperpolarization (an increased membrane potential in the direction away from the threshold potential) and it accounts for the classification of the γ-aminobutyric acid system as ‘inhibitory’. Benzodiazepines increase the inhibitory action at the γ-aminobutyric acid receptor. The γ-aminobutyric acid receptors are a group of receptors with γ-aminobutyric acid as their endogenous ligand. γ-Aminobutyric acid is the chief inhibitory neurotransmitter in the mammalian brain. Along with glycine, which primarily has effects in the spine, brainstem, and retina, it is responsible for the vast majority of all inhibitory neurotransmission in the central nervous system. Between 20% and 50% of all central synapses use γ-aminobutyric acid as their transmitter. The enzyme responsible for the formation of γ-aminobutyric acid from the amino acid glutamate is glutamic acid decarboxylase. γ-Aminobutyric acid receptors fall into two groups: ionotropic γ-aminobutyric acid A and C receptors (which are ligand-gated channels) and γ-aminobutyric acid B receptors (which are G protein-coupled receptors linked to the activation of potassium-ion channels and/or calcium-ion channels). The γ-aminobutyric acid A receptors are located postsynaptically and mediate fast synaptic inhibition (they are also known as fast receptors). These receptors are pentamers comprised of three different subunits (α, β, and γ) forming α-helices around a central ion channel. They are the targets of the actions of benzodiazepines, barbiturates, and neurosteroids and mediate sedation, excitation, and consciousness. The γ-aminobutyric acid B receptors are located pre- and postsynaptically and inhibit voltage-gated calcium-ion channels (and decrease neurotransmitter release) and open potassium-ion channels (and decrease postsynaptic membrane excitation). These receptors mediate spasticity and motor function. Similar to other benzodiazepines, midazolam produces anxiolytic, sedative, anticonvulsant, muscle relaxant, and amnesic effects. All these actions are clinically beneficial in patient management. Mild anxiolysis is the first sign to become apparent in patients receiving midazolam and with increasing drug levels the other effects become apparent. The amount of midazolam required to achieve the desired clinical effect varies on an individual basis between patients and the importance of slow titration cannot be over-emphasized. The safety profile of a drug depends on several factors, including the effects on other body systems. Midazolam exerts its main effect on the respiratory and cardiovascular systems. Respiratory system. In healthy humans midazolam may reduce the ventilatory response to carbon dioxide, leading to respiratory depression (60). However, at the dose levels used for conscious sedation only, limited effects of clinical significance have been reported (55). A respiratory effect of greater concern is apnea, the incidence being related to dose and speed of injection (56). It is essential, therefore, to communicate with the patient throughout the period of sedation to maintain respiratory function. As such, where midazolam is administered in a safe and effective way, the impact on the patient’s respiratory system will be limited. Cardiovascular system. Midazolam has been reported to produce a reduction in both systolic and diastolic blood pressure, with a simultaneous increase in heart rate (55). In a clinical setting, these changes are primarily the result of sedation and the subsequent reduction of cardiovascular function resulting from anxiety-induced sympathetic nervous system stimulation (17). The significance of these changes in healthy individuals is minimal, but does present as an issue in those with cardiovascular disease who demonstrate reduced physiological reserve. The importance of appropriate pretreatment assessment of patients for midazolam sedation cannot be over-emphasized. Once injected into the blood stream, at physiological pH, midazolam becomes lipid-soluble. This results in the drug rapidly crossing the blood–brain barrier to produce its effects on the central nervous system, which are seen as clinical signs in the patient. Midazolam has a high metabolic clearance and elimination rate, with the elimination half-life lying in the range of 1–4 hours. Both these properties result in midazolam having a relatively short duration of activity, approximately 30–40 minutes. This is an adequate period of time to allow most routine dental procedures to be carried out, although it is important to be aware that the time period will vary between individual patients. Factors influencing midazolam pharmacokinetics. The distribution and elimination of midazolam is influenced by a number of factors. Among these are age, obesity, and drug interactions. It has been demonstrated that total metabolic clearance time may increase with increasing age as a result of a slowing down of metabolism (24, 28). In obese patients, it was found that there was an increase in the deposition of midazolam into the fatty tissues, leading to an extended clearance time. The clinical impact of both these factors is that an extended recovery time is very often witnessed in such cases. An important consideration in pharmacokinetics is the effect of other drugs on the action and metabolism of midazolam. Metabolism occurs via the hepatic cytochrome p450 enzyme CYP3A4 (34). Consequently, inhibitors of CYP3A4, such as azole antifungal drugs, protease inhibitors, and erythromycin, will limit midazolam’s elimination and increase its sedative effects (47). Other drugs will enhance the sedative effect of midazolam including opioids, antidepressants, antipsychotics, and alcohol. When assessing a patient’s fitness for conscious sedation using a titrated dose of midazolam, it is important to take all these factors into consideration. One advantage of using midazolam and other benzodiazepines for sedation is the existence of an effective pharmacological reversal agent, should over-sedation occur. Flumazenil is a benzodiazepine antagonist used as a reversal agent in the treatment of benzodiazepine overdose. As this is the reversal agent for midazolam, it is important to consider its pharmacology at this stage. Flumazenil has no intrinsic activity of its own. It has a greater affinity for the benzodiazepine receptor than midazolam and reverses the effects of midazolam by competitive inhibition at the benzodiazepine-binding site on the γ-aminobutyric acid receptor. The result of this action is to reverse the sedative, respiratory depressant and cardiovascular effects of other benzodiazepines. Flumazenil is a true benzodiazepine, sharing the same basic structure as midazolam but lacking the ring structure attached to the diazepine part of the molecule. The chemical structure is illustrated in Fig. 2. Chemical structure of flumazenil. The onset of action is rapid and usually effects are seen within 1–2 minutes following intravenous administration (23). The peak effect is seen at 6–10 minutes. The recommended dose for adults is 200 μg every 1–2 minutes, until the effect is seen, to a maximum of 1 mg. It is available as a clear, colorless solution for intravenous injection, containing 500 μg in 5 ml. Many benzodiazepines have longer half-lives than flumazenil, therefore the patient must be warned of re-sedation occurring when the flumazenil has worn off (21). It is metabolized in the liver to inactive compounds, which are then excreted in the urine. Flumazenil should only be used to reverse the effects of midazolam in an emergency situation. It is worth noting that subjects who are physically dependent on benzodiazepines may suffer benzodiazepine withdrawal symptoms, including seizure upon administration of flumazenil. In such cases caution must be exercised in its use. Propofol, as an intravenous sedation agent for dental procedures, is widely used in the USA and is gaining popularity in the UK and Europe (12, 26, 38, 43, 50, 54). It is licensed as a general anesthetic agent and as such can only be administered by personnel in anesthetic use. However, to its increasing use in the field of dentistry it is important to consider it at this (2, is a intravenous agent that is widely used for the and of anesthesia and for sedation at doses in various fields of medicine. is an at and in of or propofol, and is a central nervous system It γ-aminobutyric acid A has also that the system may significantly to anesthetic action and to its unique sedative properties has a rapid onset of action with a effect and recovery is rapid use. is in and is metabolized by in the rate of clearance hepatic blood suggesting an site of elimination as The half-life elimination of propofol has been estimated to be between and hours. However, its duration of clinical effect is much because the drug is rapidly into tissues, and its therefore, off within an of This, with its rapid onset of action minutes of and the moderate it it an ideal drug for intravenous sedation when used in the appropriate Ketamine is a anesthetic from and is in use for general anesthesia and sedation in the However, as it is used for patients, it is the scope of this are to on dental pharmacology and anesthesia for of the use of in dentistry (6, sedation with nitrous oxide and is the of sedation in the UK (51, 63). However, where intravenous sedation with midazolam is in some this technique can be The administration of inhalation sedation is a technique of conscious sedation in which nitrous oxide and are employed to produce physiological changes which enhance the patient’s The patient should conscious and throughout with all The a of nitrous oxide and oxygen, to a maximum of nitrous to produce a level of sedation and anxiety control in the patient that will appropriate treatment to be carried under local A very low among dental patients has been reported with nitrous oxide sedation. during dental treatment and found the most to be of minimal clinical oxide is a It is as a at at a of When the is nitrous oxide is oxide has a of at and as such is poorly in The rate of uptake of the into the following inhalation is therefore very It does not metabolic and therefore is with other prescribed drugs. As well as an and sedative nitrous oxide produces a of and These properties are beneficial when providing dental care to patients with to moderate cardiovascular for with the of a high of As the drug is not metabolized and is from the body by it is also a sedation technique for patients with liver and is an active benzodiazepine with properties and in a similar to other benzodiazepines by the effects of γ-aminobutyric acid (Fig. main use in the field of medicine is for treatment of with other benzodiazepines, is relatively and is for who is that it can a the using the drug and/or the following Chemical structure of In can be administered to help patients a before their treatment the general level of For patients, the use of either as the sedation agent or as a before intravenous sedation, can be beneficial is available as for oral administration and is well in It has a half-life of in The adult of is before or 1 before their treatment as small as or as high as may be appropriate for some As with all other sedative agents should not be used by who are to it or other benzodiazepines. When administering similar caution should be as with midazolam, for in as by the American Society of Similar drug will be as with other benzodiazepines. For example, may enhance the effect of other central nervous system including opioids, and some and may increase blood levels of increasing the risk of its effects. As of the first benzodiazepines used for sedation in diazepam has a and of to moderate effects with minimal and no at prescribed is which the slow onset oral and has and that may have clinically significant sedative Consequently, the clinical duration of diazepam sedation to be moderate to into and a clinical effect can when this drug is into the a is in and The oral adult is administered 1 before the patient sedation with this range is not patient minimal signs of the can be increased to a total of for subsequent close to the onset of effects to verbal is as It is a of the cytochrome and that or the activity of those will affect the metabolism of diazepam (34). other oral benzodiazepines, diazepam is an excellent for patients with anxiety a dental It will not significant or and is a when those are the desired effects. the and physically should be warned that sedative effects are to last for the the patients should caution in important and may to from and during this period is of the more benzodiazepines. It has a short half-life because it is rapidly and rapidly Similar to the other benzodiazepines, is a at the receptor and the central nervous system depression produced by has a rapid short duration of and developed as a for it has the ability to a the dose of for was high when the drug was first introduced to the and the importance of medical was not emphasized Consequently, the of effects many to safety. Although commonly administered by dentists in the USA as a sedative, safety have its use in many countries. is in and The adult is administered or minutes before the that the route for administration may be more to to the oral a and must not be used there is that the patient be It is metabolized by the hepatic cytochrome enzyme system and drug involving of CYP3A4 inhibitors have been reported (34). Successful sedation local anesthesia. The local available in such as and have to be effective agents for providing pain control for surgical procedures. in local anesthesia therapeutics have the for the management of the periodontal patient. As by
Source: Periodontology 2000
Institution: Newcastle University
Language: English
Subfield: Oral Surgery
Field: Dentistry
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W1965620293